Amazon’s PillPack integrates with Blue Cross Blue Shield of Massachusetts

Amazon’s online pharmacy business, PillPack, has integrated with Blue Cross Blue Shield of Massachusetts to help members of the health plan manage their medications. The integration is the first of its kind with PillPack.

PillPack is specifically integrated with the MyBlue member app and website that enables members to manage and fill their prescriptions through the online pharmacy. Amazon acquired PillPack for roughly $1 billion last year. The integration is targeted toward those members of BCBS of Massachusetts, a not-for-profit health plan, who take multiple medications. The program is available to members of the health plan’s commercial, fully insured accounts.

"We know many of our members are managing multiple daily medications, which can cause confusion and stress," Andrew Dreyfus, president and CEO of Blue Cross Blue Shield of Massachusetts, said in a statement. "By making it easy to use PillPack, we are giving our members easy access to a simpler, more personalized experience that removes the guesswork from managing multiple medications. Members will receive automatic, reliable, clearly labeled prescriptions at their homes when they need them."

The integration means that members who choose to switch over to PillPack online don’t have to re-enter their insurance information or medication lists. The partnership between PillPack and BCBS of Massachusetts comes at no extra charge to members to order, pay for, track and receive medications to their door.

The core services provided by PillPack include:

  • Delivered, pre-sorted 30-day supply of medications
  • Customized dosing packaging with the date, time, medication name, strength and medication label with directions
  • Regular copay or co-insurance rates with no additional fees
  • 24/7 access to pharmacists via phone, email or online chat
  • Proactive contact with doctors to refill prescriptions before they run out
  • Ongoing prescription checking to prevent adverse interactions
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.